Public Employees Retirement System of Ohio Purchases Shares of 100,510 Globus Medical, Inc. $GMED

Posted by Brian Himes on Sep 2nd, 2026

Public Employees Retirement System of Ohio purchased a new position in Globus Medical, Inc. (NYSE:GMED – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 100,510 shares of the medical device company’s stock, valued at approximately $7,941,000. Public Employees Retirement System of Ohio owned 0.07% of Globus Medical at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of GMED. Sanctuary Advisors LLC lifted its stake in shares of Globus Medical by 2.3% during the 1st quarter. Sanctuary Advisors LLC now owns 6,611 shares of the medical device company’s stock valued at $570,000 after buying an additional 151 shares in the last quarter. SBI Securities Co. Ltd. increased its stake in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after buying an additional 167 shares in the last quarter. Parallel Advisors LLC raised its holdings in Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after acquiring an additional 173 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 197 shares during the period. Finally, Allworth Financial LP raised its holdings in Globus Medical by 1.6% during the fourth quarter. Allworth Financial LP now owns 12,545 shares of the medical device company’s stock valued at $1,095,000 after acquiring an additional 199 shares during the period. 95.16% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Globus Medical

In related news, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the transaction, the director directly owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Stephen T. Zarrilli sold 25,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the sale, the director owned 25,000 shares in the company, valued at $2,176,000. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. 18.38% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on GMED. Truist Financial dropped their price objective on Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Thursday, July 16th. Stifel Nicolaus lowered their price target on Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a report on Wednesday, July 8th. Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 10th. UBS Group began coverage on shares of Globus Medical in a report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price objective for the company. Finally, Wells Fargo & Company reduced their price objective on shares of Globus Medical from $103.00 to $99.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Globus Medical has a consensus rating of “Moderate Buy” and a consensus price target of $101.77.

Get Our Latest Research Report on GMED

Globus Medical Stock Down 1.3%

GMED opened at $80.32 on Wednesday. The company has a market capitalization of $10.78 billion, a PE ratio of 20.54, a price-to-earnings-growth ratio of 1.31 and a beta of 0.95. The firm has a 50-day simple moving average of $81.18 and a two-hundred day simple moving average of $84.49. Globus Medical, Inc. has a 52 week low of $54.15 and a 52 week high of $101.40.

Globus Medical (NYSE:GMED – Get Free Report) last issued its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.24. The firm had revenue of $789.61 million for the quarter, compared to analysts’ expectations of $782.88 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%.The business’s revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.86 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, sell-side analysts expect that Globus Medical, Inc. will post 4.99 earnings per share for the current year.

About Globus Medical

(Free Report)

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.